Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger.
Sorrento Therapeutics, Inc. ("STI"), a privately-held and development-stage biopharmaceutical company with a proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, has merged with a wholly-owned subsidiary of QuikByte Software, Inc. (OTC Bulletin Board: QBSW), a publicly-traded company with no active operations.
As a result of the merger, Sorrento has become a wholly-owned subsidiary of QuikByte. In connection with the consummation of the merger, QuikByte intends to change its name to "Sorrento Therapeutics, Inc."
Biotech